Efficient gene transfer to airway epithelium using recombinant Sendai virus
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Clinical studies of gene therapy for cystic fibrosis (CF) suggest that the key problem is the efficiency of gene transfer to the airway epithelium. The availability of relevant vector receptors, the transient contact time between vector and epithelium, and the barrier function of airway mucus contribute significantly to this problem. We have recently developed recombinant Sendai virus (SeV) as a new gene transfer agent. Here we show that SeV produces efficient transfection throughout the respiratory tract of both mice and ferrets in vivo, as well as in freshly obtained human nasal epithelial cells in vitro. Gene transfer efficiency was several log orders greater than with cationic liposomes or adenovirus. Even very brief contact time was sufficient to produce this effect, and levels of expression were not significantly reduced by airway mucus. Our investigations suggest that SeV may provide a useful new vector for airway gene transfer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although both methods have low reprogramming efficiency, Sendai virus-mediated reprogramming has been used for several clinical applications, notably, in cystic fibrosis, the AIDS vaccine, and other iPSC replacement therapies [29,30,31,32,33].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [29]
Citations
Cites
Fuerst, T. R., Niles, E. G., Studier, F. W., & Moss, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.21.8122 · Cited by 2,089 · cited 1×
“Recombinant SeVs were constructed and propagated as previously describe”
MethodLiposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
Caplen, N. J., Alton, E. W. F. W., Mddleton, P. G., Dorin, J. R., Stevenson, B. J., Gao, X., Durham, S. R., Jeffery, P. K., Hodson, M. E., Coutelle, C., et al. (1995) · Nature Medicine · doi:10.1038/nm0195-39 · Cited by 711
Zabner, J., Couture, L. A., Gregory, R. J., Graham, S. M., Smith, A. E., & Welsh, M. J. (1993) · Cell · doi:10.1016/0092-8674(93)80063-k · Cited by 681
Submucosal glands are the predominant site of CFTR expression in the human bronchus
Engelhardt, J. F., Yankaskas, J. R., Ernst, S. A., Yang, Y., Marino, C. R., Boucher, R. C., Cohn, J. A., & Wilson, J. M. (1992) · Nature Genetics · doi:10.1038/ng1192-240 · Cited by 653 · cited 1×
“2E ), the predominant site of CFTR expression in the human bronchu”
BackgroundLee, E. R., Marshall, J., Siegel, C. S., Jiang, C., Yew, N. S., Nichols, M. R., Nietupski, J. B., Ziegler, R. J., Lane, M. B., Wang, K. X., et al. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.14-1701 · Cited by 443 · cited 1×
“, or the plasmid pCMV-luc complexed to GL-67/DOPE/DMPE-PEG 5000 (80 μg DNA/mouse) were placed as a single 100 μl bolus into the nasal cavity of male BALB/c mice (six to eight weeks), and the solution was sniffed into the lung”
MethodEfficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis
Johnson, L. G., Olsen, J. C., Sarkadi, B., Moore, K. L., Swanstrom, R., & Boucher, R. C. (1992) · Nature Genetics · doi:10.1038/ng0992-21 · Cited by 439 · cited 1×
“Laboratory studies suggest that correction of the CF chloride defect can be achieved by introducing ∼6–10% of corrected cells overexpressing CFTR into a CF monolaye”
BackgroundAlton, E., Stern, M., Farley, R., Jaffe, A., Chadwick, S., Phillips, J., Davies, J., Smith, S., Browning, J., Davies, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06532-5 · Cited by 435
Porteous, D., Dorin, Jr., McLachlan, G., Davidson-Smith, H., Davidson, H., Stevenson, B., Carothers, A., Wallace, W., Moralee, S., Hoenes, C., et al. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300390 · Cited by 324
Specific gangliosides function as host cell receptors for Sendai virus.
Markwell, M. A., Svennerholm, L., & Paulson, J. C. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5406 · Cited by 259 · cited 1×
“The receptor for SeV is sialic acid bound to gangliosides, present on most cell types, including the apical surface of the conducting airway”
BackgroundExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo
Ferrari, S., Moro, E., Pettenazzo, A., Behr, J., Zacchello, F., & Scarpa, M. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300503 · Cited by 256 · cited 1×
“Two days post infection, ferrets were killed and the lungs fixed by intratracheal perfusion of fixative solution, excised en bloc, processed, and stained with X-Gal as described by Ferrari and colleague”
Method
Cited by
Items 101–200 of 244
Ignáth, I., Hegyi, P. J., Venglovecz, V., Székely, C. A., Carr, G., Hasegawa, M., Inoue, M., Takács, T., Argent, B. E., Gray, M. A., et al. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181b65d34 · Cited by 26
“Recombinant SeV Constructs and Infection of CFPAC-1 Cells Sendai virus constructs containing the wild-type CFTR (SeV-CFTR) or the A-galactosidase (SeV-LacZ) gene were prepared as described previously.(9,10) CFPAC-1 monolayers were infected with SeV-CFTR or SeV-LacZ (nuclear localized) from the apical side 3 days after…”
MethodRecombinant Sendai virus vectors for activated T lymphocytes
Okano, S., Yonemitsu, Y., Nagata, S., Sata, S., Onimaru, M., Nakagawa, K., Tomita, Y., Kishihara, K., Hashimoto, S., Nakashima, Y., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301998 · Cited by 25
Tatsuta, K., Tanaka, S., Tajiri, T., Shibata, S., Komaru, A., Ueda, Y., Inoue, M., Hasegawa, M., Suita, S., Sueishi, K., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.161 · Cited by 26
Current prospects for gene therapy of cystic fibrosis
Ziady, A. G., & DAVIS, P. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.04.008 · Cited by 26
Cystic fibrosis gene therapy: a mutation-independent treatment
Griesenbach, U., Davies, J. C., & Alton, E. W. F. W. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000327 · Cited by 29
Schaerlaekens, S., Jacobs, L., Stobbelaar, K., Cos, P., & Delputte, P. (2024) · Vaccines · doi:10.3390/vaccines12010097 · Cited by 29
Harada, Y., Okada-Nakanishi, Y., Ueda, Y., Tsujitani, S., Saito, S., Fuji-Ogawa, T., Iida, A., Hasegawa, M., Ichikawa, T., & Yonemitsu, Y. (2011) · Scientific Reports · doi:10.1038/srep00174 · Cited by 25
Shirakura, M., Fukumura, M., Inoue, M., FUJIKAWA, S., Maeda, M., Watabe, K., Kyuwa, S., Yoshikawa, Y., & Hasegawa, M. (2003) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.52.119 · Cited by 25
“In addition, SeV vector shows potent infectivity in most mammalian cells including differentiated ones such as neuronal and muscular cells and directs high-level gene expression in these cells [17, 22, 27, 31].”
BackgroundInduction of Influenza-Specific Mucosal Immunity by an Attenuated Recombinant Sendai Virus
Le, T.-V. L., Mironova, E., Garcin, D., & Compans, R. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018780 · Cited by 27
“Sendai virus naturally infects the respiratory tract of mice and recombinant viruses have been reported to efficiently transduce luciferase, lac Z and green fluorescent protein (GFP) genes in the airways of mice or ferrets as well as primary human nasal epithelial cells [16].”
BackgroundInfluentialPre-clinical and clinical endpoint assays for cystic fibrosis gene therapy
Uta Griesenbach, D., & Boyd, A. C. (2005) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2005.02.002 · Cited by 24
“perfusion of GTA onto the mouse turbinate via a thin catheter ensures prolonged contact time with the epithelial surface [14] and allows characterisation of GTAs without the added complication of limited contact time.”
BackgroundMethodGene Therapy for Airway Diseases
Pilewski, J. M. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.27.2.f244 · Cited by 23
“Lastly, novel replication-incompetent viruses that have greater tropism for airway epithelial cells than adenovirus or AAV, such as respiratory syncytial virus (65) and Sendai virus (66), have been developed and reported to mediate efficient gene transfer to human airway.”
BackgroundCellular unfolded protein response against viruses used in gene therapy
Sen, D., Balakrishnan, B., & Jayandharan, G. R. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00250 · Cited by 27
“…cells Herpesvirus-HSV-1 ∼152 kb dsDNA, icosahedric enveloped, ∼125 nm diameter Yes ∼150 kb No Only dividing cells Large transgene carrying capacity, production of high titres Host immune response, short term gene expression used in gene therapy is important to further optimize gene delivery.”
BackgroundGene therapy for cystic fibrosis
Boyd, A. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.1.1 · Cited by 23
Ban, H., Inoue, M., Uta Griesenbach, D., Munkonge, F. M., Chan, M., Iida, A., Alton, E. W. F. W., & Hasegawa, M. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303032 · Cited by 22
Duan, X., Yonemitsu, Y., Chou, B., Yoshida, K., Tanaka, S., Hasegawa, M., Tetsutani, K., Ishida, H., Himeno, K., & Hisaeda, H. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.08.026 · Cited by 22
Tan, M., Reyes‐Ortega, F., & Schneider‐Futschik, E. K. (2020) · Magnetochemistry · doi:10.3390/magnetochemistry6020025 · Cited by 25
Sasaki, K., Inoue, M., Shibata, H., Ueda, Y., Muramatsu, S., Okada, T., Hasegawa, M., OZAWA, K., & Hanazono, Y. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302409 · Cited by 22
Shoji, T., Yonemitsu, Y., Komori, K., Tanii, M., Itoh, H., Sata, S., Shimokawa, H., Hasegawa, M., Sueishi, K., & Maehara, Y. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00996.2002 · Cited by 22
“The high-titer stocks of recombinant SeVs used in this study were prepared as described previously (7, 13, 17, 29, 32, 33).”
MethodNew cancer therapy using genetically-engineered oncolytic Sendai virus vector
Kinoh, H. (2007) · Frontiers in bioscience · doi:10.2741/2847 · Cited by 20
Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen
Yonemitsu, Y. (2007) · Frontiers in bioscience · doi:10.2741/2809 · Cited by 20
Toward Novel Vaccines and Therapies Based on Negative-Strand RNA Viruses
von Messling, V., & Cattaneo, R. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-06099-5_8 · Cited by 20
Griesenbach, U., Boyton, R. J., Somerton, L., Garcia, S. E., Ferrari, S., Owaki, T., Ya-Fen, Z., Geddes, D. M., Hasegawa, M., Altmann, D. M., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302677 · Cited by 24
Kato, T., Ueda, Y., Kinoh, H., Yoneyama, Y., Matsunaga, A., Komaru, A., Harada, Y., Suzuki, H., Komiya, A., Shibata, S., et al. (2010) · Neoplasia · doi:10.1593/neo.10732 · Cited by 19
Murakami, Y., Ikeda, Y., Yonemitsu, Y., Tanaka, S., Kondo, H., Okano, S., Kohno, R.-I., Miyazaki, M., Inoue, M., Hasegawa, M., et al. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1142 · Cited by 19
“SeV makes use of sialic acid residue on surface glycoproteins or asialoglycoprotein present as a receptor [5,6], and SeV-derived vectors (recombinant SeV: rSeV) have been shown to infect various types of mammalian cells, such as airway epithelial, skeletal muscle, ependymal and vascular endothelial cells, and produce…”
BackgroundSendai viral vector mediated angiopoietin-1 gene transfer for experimental ischemic limb disease
Huang, J., Inoue, M., Hasegawa, M., Tomihara, K., Tanaka, T., Chen, J., & Hamada, H. (2009) · Angiogenesis · doi:10.1007/s10456-009-9144-6 · Cited by 18
“Sendai virus vector has been reported [14–19].”
Inoue, H., Iga, M., Nabeta, H., Yokoo, T., Suehiro, Y., Okano, S., Inoue, M., Kinoh, H., Katagiri, T., Takayama, K., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00964.x · Cited by 22
Identification of transfected cell types following non‐viral gene transfer to the murine lung
Davies, L. A., Seguela, C., Varathalingam, A., Cheng, S. H., Hyde, S. C., & Gill, D. R. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1007 · Cited by 17
“Convincing ß-Gal staining can be achieved with vectors that generate high levels of reporter gene expression, such as adenoviral vectors [15,16] or Sendai virus vectors [17].”
BackgroundOkano, S., Yonemitsu, Y., Shirabe, K., Kakeji, Y., Maehara, Y., Harada, M., Yoshikai, Y., Inoue, M., Hasegawa, M., & Sueishi, K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901641 · Cited by 21
Boyd, A. (2005) · KARGER eBooks · doi:10.1159/000088601 · Cited by 17
Kawachi, M., Tamai, K., Saga, K., Yamazaki, T., Fujita, H., Shimbo, T., Kikuchi, Y., Nimura, K., Nishifuji, K., Amagai, M., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.046 · Cited by 17
Bitzer, M., Ungerechts, G., Bossow, S., Graepler, F., Sedlmeier, R., Armeanu, S., Bernloehr, C., Spiegel, M., Gross, C. D., Gregor, M., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00052-7 · Cited by 17
Efficient propagation of single gene deleted recombinant Sendai virus vectors
Bernloehr, C., Bossow, S., Ungerechts, G., Armeanu, S., Neubert, W. J., Lauer, U. M., & Bitzer, M. (2004) · Virus Research · doi:10.1016/j.virusres.2003.11.005 · Cited by 16
Mizokami, D., Araki, K., Tanaka, N. K., Suzuki, H., Tomifuji, M., Yamashita, T., Ueda, Y., Shimada, H., Matsushita, K., & Shiotani, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116279 · Cited by 18
“The sendai virus (SeV) has a strong affinity to the airway epithelium.[6, 7] The wild-type form of SeV causes respiratory tract infections in rodents, but is not pathogenic in humans.”
BackgroundGene Therapy for Recurrent Laryngeal Nerve Injury
Araki, K., Suzuki, H., Uno, K., Tomifuji, M., & Shiotani, A. (2018) · Genes · doi:10.3390/genes9070316 · Cited by 16
“Furthermore, high gene-transduction efficiencies have been reported in many tissues, including the airway epithelial [25,26], inner ear [27], muscle [28] and neural [29] tissues.”
BackgroundRecombinant Sendai Virus-Mediated Gene Transfer to Adipose Tissue-Derived Stem Cells (ASCs)
Yukawa, H., Noguchi, H., Oishi, K., Miyazaki, T., Kitagawa, Y., Inoue, M., Hasegawa, M., & Hayashi, S. (2008) · Cell Transplantation · doi:10.3727/000000008783907071 · Cited by 16
Sendai Virus-Mediated Gene Delivery into Hepatocytes via Isolated Hepatic Perfusion
Fujita, S., Eguchi, A., Okabe, J., Harada, A., Sasaki, K., Ogiwara, N., Inoue, Y., Ito, T., Matsuda, H., Kataoka, K., et al. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.1728 · Cited by 15
In vivo imaging of gene transfer to the respiratory tract
Uta Griesenbach, D., Meng, C., Farley, R., Cheng, S. H., Scheule, R. K., Davies, M. H., Wolstenholme-Hogg, P. C., ten Hove, W., van der Hoeven, P., Sinn, P. L., et al. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.11.017 · Cited by 14
De novo generation of a non-segmented negative strand RNA virus with a bicistronic gene
Touzelet, O., Loukili, N., Pelet, T., Fairley, D., Curran, J. A., & Power, U. F. (2008) · Virus Research · doi:10.1016/j.virusres.2008.10.019 · Cited by 15
Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus
Waddington, S. N., Buckley, S. M. K., Bernloehr, C., Bossow, S., Ungerechts, G., Cook, T. H., Gregory, L. G., Rahim, A. A., Themis, M., Neubert, W., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302205 · Cited by 15
Zelmer, A., Krusch, S., Koschinski, A., Rohde, M., Repp, H., Chakraborty, T., & Weiß, S. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.764 · Cited by 15
Perspectives on Gene Therapy for Cystic Fibrosis Airway Disease
Bigger, B., & Coutelle, C. (2001) · BioDrugs · doi:10.2165/00063030-200115090-00006 · Cited by 17
“Replication competent Sendai virus has receptors specific to the apical surface of epithelial cells and has recently shown highly efficient transduction of animal respiratory tracts.[133]”
Sugiyama, M., Kakeji, Y., Tsujitani, S., Harada, Y., Onimaru, M., Yoshida, K., Tanaka, S., Emi, Y., Morita, M., Morodomi, Y., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0479 · Cited by 15
“SeV, a member of the family Paramyxoviridae, have a nonsegmented negative-strand RNA genome and shows a broad spectrum of gene transfer (10-12), including DCs (7-9).”
BackgroundViral vectors for cystic fibrosis gene therapy: What does the future hold?
Griesenbach, U., Inoue, Hasegawa, & Alton, E. W. F. W. (2010) · Virus Adaptation and Treatment · doi:10.2147/vaat.s8887 · Cited by 14
“CF sputum has been shown to be a significant barrier to nonviral gene transfer,(7,8) but importantly does not appear to affect viral vectors, such as Sendai virus (SeV) and adenovirus (Ad), to the same degree.(7,8) The airways down to the level of the primary bronchioles are lined by ciliated airway epithelial cells (…”
The role of doxorubicin in non-viral gene transfer in the lung
Uta Griesenbach, D., Meng, C., Farley, R., Gardner, A. I., Brake, M. A., Frankel, G. M., Gruenert, D. C., Cheng, S. H., Scheule, R. K., & Alton, E. W. F. W. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.037 · Cited by 14
“However, the efficiency of non-viral gene transfer is comparatively low compared to viral vectors, such as for example Sendai virus [10], and it is currently unclear, if non-viral gene therapy can ameliorate the chronic lung infection and inflammation that causes most morbidity and mortality in CF subjects.”
BackgroundSendai virus transgene in a novel gene therapy for laryngotracheal disease
Mizokami, D., Araki, K., Tanaka, N. K., Suzuki, H., Tomifuji, M., Yamashita, T., Inoue, M., Hasegawa, M., & Shiotani, A. (2013) · The Laryngoscope · doi:10.1002/lary.23917 · Cited by 13
“A previous report showed that the SeV vector has a very efficient transduction rate, up to 70% to 80%, in bronchial epithelial cells.(1) Laryngeal epithelium is histologically similar to respiratory epithelium, such as that of the trachea or bronchus; therefore, in this study, we examined the efficiency of SeV transdu…”
BackgroundMatsushita, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4316 · Cited by 13
Progress towards gene therapy for cystic fibrosis
Tate, S., & Elborn, J. S. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.2.269 · Cited by 15
“Recombinant SeV-mediated gene transfer to differentiated airway epithelial cells has shown to be very efficient both in mice and ferrets [67,68].”
Elevated gastrin secretion by in vivo gene electroporation in skeletal muscle
Yasui, A., Oda, K., Usunomiya, H., Kakudo, K., Suzuki, T., Yoshida, T., Park, H.-M., Fukazawa, K., & Muramatsu, T. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.8.5.489 · Cited by 14
Airway gene therapy and cystic fibrosis
Parsons, D. (2005) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2005.00556.x · Cited by 12
Gene Therapy: A Possible Alternative to CFTR Modulators?
Mercier, J., Ruffin, M., Corvol, H., & Guillot, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648203 · Cited by 13
“Indeed, mucus, mucociliary clearance, and lung immune responses complicate the entry of the gene transfer agent into target cells, and the few that succeed encounters a new obstacle: the nuclear membrane (Yonemitsu et al., 2000; Stern et al., 2003; Schuster et al., 2014; Xia et al., 2014).”
BackgroundTelomerase-specific virotherapy for human squamous cell carcinoma
Fujiwara, T. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802715731 · Cited by 12
“Because of this property, many viruses have been adapted as gene transfer vectors [1-7] .”
BackgroundProspects for gene therapy in lung disease
Davies, J. C. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00048-0 · Cited by 11
Royal, R., Kershaw, M. H., Reeves, M., Wang, G., Daly, T., Treisman, J. S., Lam, J. Y. J., & Hwu, P. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301734 · Cited by 12
Genetic cell reprogramming: A new technology for basic research and applied usage
Bogomazova, A. N., Vassina, E. M., Киселев, С. Л., Lagarkova, M. A., Lebedeva, O. S., Nekrasov, E. D., Panova, A. V., Philonenko, E. S., Khomyakova, E. A., Lv, T., et al. (2015) · Russian Journal of Genetics · doi:10.1134/s102279541504002x · Cited by 11
Genomic Context Vectors and Artificial Chromosomes for Cystic Fibrosis Gene Therapy
Conese, M., Boyd, A., Gioia, S. D., Auriche, C., & Ascenzioni, F. (2007) · Current Gene Therapy · doi:10.2174/156652307780859026 · Cited by 11
“Recombinant SeV is a very efficient gene transfer agent for airway epithelial cells partly because it does not need to enter the nucleus [Yonemitsu et al. 2000; Griesenbach et al. 2006b].”
BackgroundThe occurrence and development of induced pluripotent stem cells
Chen, Y., Li, M., & Wu, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1389558 · Cited by 18
Cell cycle independent infection and gene transfer by recombinant Sendai viruses
Armeanu, S., Ungerechts, G., Bernloehr, C., Bossow, S., Gregor, M., Neubert, W. J., Lauer, U. M., & Bitzer, M. (2003) · Journal of Virological Methods · doi:10.1016/s0166-0934(02)00280-x · Cited by 10
Bossow, S. (2012) · The Open Virology Journal · doi:10.2174/1874357901206010073 · Cited by 9
“A 3 h incubation time served as reference (initial amount of 5 x 10 5 input genomes), ensuring that virus adsorption and internalization is completed [19] and primary transcription is initialized [20].”
MethodConcept and Technology Underlying Sendai Virus (SeV) Vector Development
Iida, A., & Inoue, M. (2013) · Springer eBooks · doi:10.1007/978-4-431-54556-9_3 · Cited by 9
Gene therapy for cystic fibrosis: recent progress and current aims
Paul-Smith, M. C., Bell, R. V., Alton, W. E., Alton, E. W. F. W., & Griesenbach, U. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1180974 · Cited by 12
Yukawa, H., Noguchi, H., Oishi, K., Inoue, M., Hasegawa, M., Hamaguchi, M., Hamajima, N., & Hayashi, S. (2009) · Cell Transplantation · doi:10.1177/096368970901805-616 · Cited by 9
Tanaka, S., Yonemitsu, Y., Yoshida, K., Okano, S., Kondo, H., Inoue, M., Hasegawa, M., Masumoto, K., Suita, S., Taguchi, T., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302955 · Cited by 9
RECOMBINANT SENDAI VIRUS FOR EFFICIENT GENE TRANSFER TO HUMAN AIRWAY EPITHELIUM
Pinkenburg, O., Vogelmeier, C. F., Bossow, S., Neubert, W. J., Lutz, R. B., Ungerechts, G., Lauer, U. M., Bitzer, M., & Bals, R. (2004) · Experimental Lung Research · doi:10.1080/01902140490266501 · Cited by 9
“Also, undifferentiated human nasal cells were efficiently infected by rSeV [8].”
BackgroundImmunostimulatory virotherapy using recombinant sendai virus as a new cancer therapeutic regimen
Yonemitsu, Y. (2008) · Frontiers in bioscience · doi:10.2741/3054 · Cited by 9
“In the case of rSeV vector, transgene expression is frequently 100,000 times higher compared to the case when adenoviral vectors are used (5).”
BackgroundKwak, G., Lee, D., & Suk, J. S. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2282535 · Cited by 10
“LV vector envelops were also extensively pseudotyped with various glycoproteins from diverse viral families with known lung epithelium tropism, including filovirus [152], coronavirus [153], baculovirus [106], and Sendai virus [111,154].”
BackgroundTanaka, N. K., Araki, K., Mizokami, D., Miyagawa, Y., Yamashita, T., Tomifuji, M., Ueda, Y., Inoue, M., Matsushita, K., Nomura, F., et al. (2015) · Gene Therapy · doi:10.1038/gt.2014.123 · Cited by 8
(2007) · Wiley eBooks · doi:10.1002/9780470184585 · Cited by 8
Cytokine-Based Log-Scale Expansion of Functional Murine Dendritic Cells
Harada, Y., Ueda, Y., Kinoh, H., Komaru, A., Fuji-Ogawa, T., Furuya, A., Iida, A., Hasegawa, M., Ichikawa, T., & Yonemitsu, Y. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006674 · Cited by 8
“The virus yields are expressed in cell infectious units (CIU) [17,18].”
BackgroundKaneko, K., Yonemitsu, Y., Fujii, T., Onimaru, M., Jin, C.-H., Inoue, M., Hasegawa, M., Onohara, T., Maehara, Y., & Sueishi, K. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01006.2005 · Cited by 8
“High titer stocks of SeVs expressing human FGF-2 (SeV-hFGF2) and firefly luciferase (SeVluciferase) used in this study were prepared as described previously (19, 21, 32, 37).”
BackgroundMethodP95 Assessment of F/HN-pseudotyped Lentivirus as a Clinically Relevant Vector For Lung Gene Therapy
Uta Griesenbach, D., Inoue, M., Meng, C., Farley, R., Chan, M., Newman, N., Brum, A. M., You, J., Kerton, A., Shoemark, A., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202678.337 · Cited by 8
Matsumoto, T., Tanaka, M., Yoshiya, K., Yoshiga, R., Matsubara, Y., Horiuchi-Yoshida, K., Yonemitsu, Y., & Maehara, Y. (2016) · Scientific Reports · doi:10.1038/srep30035 · Cited by 7
Intranasal Sendai virus‐based SARS‐CoV ‐2 vaccine using a mouse model
Morimoto, S., Saeki, K., Takeshita, M., Hirano, K., Shirakawa, M., Yamada, Y., Nakamura, S., Ozawa, F., & Okano, H. (2022) · Genes to Cells · doi:10.1111/gtc.12992 · Cited by 6
“First, the SeV vector has a high gene expression capacity and showed about 2500-fold transduced target expression compared with adenovirus vectors (Yonemitsu et al., 2000).”
BackgroundRecombinant Sendai Virus-Mediated Gene Transfer to Mouse Pancreatic Stem Cells
Oishi, K., Noguchi, H., Yukawa, H., Inoue, M., Takagi, S., Iwata, H., Hasegawa, M., & Hayashi, S. (2009) · Cell Transplantation · doi:10.1177/096368970901805-613 · Cited by 7
Gene therapy for cystic fibrosis
Conese, M., Gioia, S. D., & Castellani, S. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.8.929 · Cited by 9
“The inventors have also found that the recombinant SeV vector efficiently introduced the exogenous genes not only to permissive mouse respiratory tracts but also to non-permissive airway epithelial cells of large animals such as ferret, sheep and human [99] .”
BackgroundJIHOČESKÁ UNIVERZITA V ČESKÝCH BUDĚJOVICÍCH
Fakulta, P. (2012) · Cited by 7
Alton, E. W. F. W., Geddes, D. M., & Davies, J. C. (2003) · CRC Press eBooks · doi:10.1201/9780203912331.ch14 · Cited by 7
Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells
Grygoryev, D., Ekstrom, T. J., Manalo, E. C., Link, J. M., Alshaikh, A., Keith, D., Allen-Petersen, B. L., Sheppard, B. C., Morgan, T. K., Soufi, A., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27221 · Cited by 6
Dramatic improvement of DC-based immunotherapy against various malignancies
Harada, Y. (2011) · Frontiers in bioscience · doi:10.2741/3850 · Cited by 6
“As SeV uses a cytoplasmic transcription system, it can mediate gene transfer to a cytoplasmic location, avoiding possible malignant transformation due to genetic alteration of host cells (40, 41); this is a safety advantage of SeV.”
BackgroundA Bond-Fluctuation Model of Translational Dynamics of Chain-like Particles through Mucosal Scaffolds
Bajd, F., & Serša, I. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.04.031 · Cited by 6
“There is a great research interest in developing new drugdelivery vehicles, viral (13) and nonviral (1), with a high mucus-penetrating potential.”
BackgroundProduction of therapeutic iduronate‐2‐sulfatase enzyme with a novel single‐stranded RNA virus vector
Ohira, M., Kikuchi, E., Mizuta, S., Yoshida, N., Onodera, M., Nakanishi, M., Okuyama, T., & Mashima, R. (2021) · Genes to Cells · doi:10.1111/gtc.12894 · Cited by 6
Šimara, P., Tesařová, L., Paďourová, S., & Koutná, I. (2014) · Folia Biologica · doi:10.14712/fb2014060s10085 · Cited by 8
“A negative-strand RNA virus does not go through DNA phase and replicates only in the cytoplasm, and is therefore very suitable as a vector for human gene therapy ( Yonemitsu et al., 2000; Masaki et al., 2001; Tokusumi et al., 2002; Ferrari et al., 2007).”
Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
Gómez, Á., & Reina, R. (2025) · Viruses · doi:10.3390/v17050737 · Cited by 7
“rSeVv can infect in vitro and in vivo multiple mammalian cell types, with a primary replication site in the respiratory epithelium [8,68,69].”
Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine
Dhanjal, D. S., Singh, R., Sharma, V., Nepovimová, E., Adam, V., Kuča, K., & Chopra, C. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230503144619 · Cited by 5
Armeanu, S., Bitzer, M., Smirnow, I., Bossow, S., Appel, S., Ungerechts, G., Bernloehr, C., Neubert, W. J., Lauer, U. M., & Brossart, P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.4971 · Cited by 6
“Extraordinary features of SeV are a remarkably brief contact time that is necessary for cellular uptake (15, 16), a strong but adjustable expression of foreign genes (17), a cell cycle-independent transduction of target cells (18), and an exclusively cytoplasmic localized replication Departments of Internal Medicine *…”
BackgroundAdvances in RNA Viral Vector Technology to Reprogram Somatic Cells: The Paramyxovirus Wave
Sharp, B., Rallabandi, R., & Devaux, P. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00599-x · Cited by 5
Wiegand, M. A., Savellini, G. G., Martorelli, B., Bossow, S., Neubert, W. J., & Cusi, M. G. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.06.053 · Cited by 7
Recent Developments in Patented DC-Based Immunotherapy for Various Malignancies
Harada, Y., & Yonemitsu, Y. (2011) · Recent Patents on Regenerative Medicine · doi:10.2174/2210296511101010072 · Cited by 5
A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing
Stevens, C. S., Carmichael, J. C., Watkinson, R., Kowdle, S., Reis, R. A., Hamane, K., Jang, J., Park, A., Pernet, O., Khamaikawin, W., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00832-24 · Cited by 6
Yoshida, K., Yonemitsu, Y., Tanaka, S., Yoshida, S., Shibata, S., Kondo, H., Okano, S., Ishikawa, F., Akashi, K., Inoue, M., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.111 · Cited by 4
Tourists’ Satisfaction on the Use of Biometrics Technology: A Conceptual Framework
Neo, H.-F., Devinaga, R., Tong, D. Y. K., & Teo, C.-C. (2013) · Journal of Economics Business and Management · doi:10.7763/joebm.2015.v3.162 · Cited by 4
Kawakubo, N., Tanaka, S., Kinoshita, Y., Tajiri, T., Yonemitsu, Y., & Taguchi, T. (2017) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2017.08.019 · Cited by 4
Roth, J., Li, J. K.-K., & Barnard, D. L. (2010) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc15f01s17 · Cited by 4
“…example, a recombinant SeV, which is nonpathogenic to humans is a prime candidate for vaccine development and gene transfer, has been used as an expression vector in gene transfer to deliver foreign eukaryotic genes to neurons and airway epithelium (Yonemitsu et al., 2000; Shirakura et al., 2003).”
BackgroundSendai Virus-Based Oncolytic Gene Therapy
Morodomi, Y., Inoue, M., Hasegawa, M., Okamoto, T., Maehara, Y., & Yonemitsu, Y. (2013) · InTech eBooks · doi:10.5772/55328 · Cited by 4
“Sialic acid is widely expressed in the cells of mammals or other species, and its expression enables a large variety of SeV infections, such as those in the airway epithelium [5], saphenous vein [6], or in a variety of tumors [7,8].”
BackgroundLung Gene Therapy: Clinical and Regulatory Issues
Amrite, A. C., Cheruvu, N. P. S., Sundaram, S., Aravalli, R. N., Cheng, P., & Kompella, U. B. (2004) · Clinical Research and Regulatory Affairs · doi:10.1081/crp-120039559 · Cited by 4
Yonemitsu, Y., Matsumoto, T., & Maehara, Y. (2013) · Springer eBooks · doi:10.1007/978-4-431-54556-9_8 · Cited by 3
Collaco, J. M., & Cutting, G. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812532-8.00012-4 · Cited by 3
Kishi, Y., Inoue, M., Tanaka, Y., Shibata, H., Masuda, S., Ikeda, T., Hasegawa, M., & Hanazono, Y. (2008) · Cloning and Stem Cells · doi:10.1089/clo.2007.0080 · Cited by 3
“SeV vectors replicate exclusively in the cytoplasm of transduced cells, and do not go through a DNA phase (Bitzer et al., 2003; Li et al., 2000; Yonemitsu et al., 2000); therefore, there is no concern about the unwanted integration of foreign sequences into chromosomal DNA of the host, which might…”
New Genetic and Pharmacological Treatments for Cystic Fibrosis
Conese, M., Romano, M., Furnari, M. L., Copreni, E., Fino, I. D., Pardo, F., & Galietta, L. J. V. (2009) · Current Pediatric Reviews · doi:10.2174/157339609787587555 · Cited by 3
“Sendai virus (SeV), a member of the same family, has a number of advantages for CFTR gene delivery [162]: 1) SeV is able to penenetrate the overlying”
BackgroundCytoplasmic RNA Vector Derived from Nontransmissible Sendai Virus: Production and Use
Iida, A., & Hasegawa, M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-141-8:361 · Cited by 3
Molecular Therapies for Cystic Fibrosis
Davies, G., Griesenbach, U., Alton, E. W. F. W., & Davies, J. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44887-1.00053-5 · Cited by 6
Metadata
- Authors
- Yonemitsu, Y., Kitson, C., Ferrari, S., Farley, R., Griesenbach, U., Judd, D., Steel, R., Scheid, P., Zhu, J., Jeffery, P. K., Kato, A., Hasan, M. K., Nagai, Y., Masaki, I., Fukumura, M., Hasegawa, M., Geddes, D. M., & Alton, E. W. F. W.
- Affiliations
- Imperial College London (GB)
- National Institute of Infectious Diseases (JP)
- Kyushu University (JP)
- ID Pharma (Japan) (JP)
- Corresponding author
- Alton, Eric W.F.W.
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2000-09
- Volume
- 18
- Issue
- 9
- Pages
- 970-973
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1553961669
- Cited by
- 244
- References
- 25
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 10 · 2016: 11 · 2015: 5 · 2014: 7 · 2013: 11 · 2012: 8
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- cystic fibrosis gene therapy, nasal epithelial cells, cationic liposomes, ferrets, mice
- MeSH terms
- Adenoviridae, Animals, Bronchi, Cell Line, Cells, Cultured, Cystic Fibrosis, Dogs, Dose-Response Relationship, Drug, Epithelium, Female, Ferrets, Genetic Vectors, Humans, Liposomes, Luciferases, Lung, Male, Mice, Inbred BALB C, Mucous Membrane, Nasal Mucosa, Receptors, Cell Surface, Sheep, Time Factors, Trachea, Transfection, Gene Transfer Techniques, Respirovirus, COS Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.